| __timestamp | BioCryst Pharmaceuticals, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 51796000 | 94231000 |
| Thursday, January 1, 2015 | 72758000 | 146394000 |
| Friday, January 1, 2016 | 61008000 | 188272000 |
| Sunday, January 1, 2017 | 66962000 | 166707000 |
| Monday, January 1, 2018 | 84888000 | 401843000 |
| Tuesday, January 1, 2019 | 107068000 | 560909000 |
| Wednesday, January 1, 2020 | 122964000 | 722343000 |
| Friday, January 1, 2021 | 208808000 | 771182000 |
| Saturday, January 1, 2022 | 253297000 | 877090000 |
| Sunday, January 1, 2023 | 216566000 | 877387000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Sarepta Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting approaches to R&D investment.
From 2014 to 2023, Sarepta Therapeutics has consistently outpaced BioCryst Pharmaceuticals in R&D spending. In 2023, Sarepta's R&D expenses were nearly four times higher than BioCryst's, highlighting its aggressive pursuit of innovation. This trend has been evident since 2018, when Sarepta's R&D spending surged, reaching a peak in 2022.
While BioCryst has shown a steady increase in R&D investment, with a notable 300% rise from 2014 to 2022, Sarepta's spending has grown by over 800% in the same period. This disparity underscores Sarepta's strategic focus on pioneering advancements in the biotech sector.
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
argenx SE or Sarepta Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Investment: argenx SE vs BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc.
BeiGene, Ltd. vs Sarepta Therapeutics, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Sarepta Therapeutics, Inc. and Exelixis, Inc. Allocate Funds
R&D Insights: How Sarepta Therapeutics, Inc. and PTC Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and MannKind Corporation
Research and Development Investment: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.
Comparing Innovation Spending: Agios Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BioCryst Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.